BRACAnalysis
This article was originally published in The Gray Sheet
Executive Summary
Myriad Genetic's breast and ovarian cancer genetic predisposition test is used in CLIA laboratories. It is not a CLIA-waived test, as was reported (1"The Gray Sheet" Sept. 16, 2002, p. 20)...
You may also be interested in...
Myriad Genetics DTC Ads For BRACAnalysis To Focus On Prevention Market
Myriad Genetics will concentrate direct-to-consumer advertising in Atlanta and Denver for its BRACAnalysis breast and ovarian cancer genetic predisposition testing service as the firm moves beyond physician education as a sole means of promotion
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.